Ken Herrmann

Summary

Country: Germany

Publications

  1. ncbi Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI
    Ken Herrmann
    Department of Nuclear Medicine, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
    Mol Imaging Biol 13:1011-9. 2011
  2. ncbi Monitoring response to therapeutic interventions in patients with cancer
    Ken Herrmann
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    Semin Nucl Med 39:210-32. 2009
  3. ncbi Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment
    Ken Herrmann
    Department of Nuclear Medicine, Technische Universitaet Muenchen, Munich, Germany
    J Nucl Med 52:690-6. 2011
  4. ncbi Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study
    Katja Ott
    Department of Surgery, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 14:2012-8. 2008
  5. ncbi Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine
    Florian Eckel
    Department of Internal Medicine II, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 50:1441-7. 2009
  6. ncbi [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer
    Murat Tuncel
    Department of Nuclear Medicine, Klinikum rechts der lsar, Technische Universitat Munchen, Munich, Germany
    Nucl Med Biol 35:689-95. 2008
  7. ncbi PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
    Florian Lordick
    Department of Surgery, Clinic rechts der Isar, Technical University of Munich, Munich, Germany
    Lancet Oncol 8:797-805. 2007
  8. ncbi A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma
    Ken Herrmann
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 52:1898-902. 2011
  9. ncbi (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial
    Christian Meyer Zum Büschenfelde
    3rd Department of Medicine Haematology and Medical Oncology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 52:1189-96. 2011
  10. ncbi Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction
    Hinrich A Wieder
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaningerstrasse 22, Munich, Germany
    Eur J Nucl Med Mol Imaging 34:1925-32. 2007

Collaborators

Detail Information

Publications37

  1. ncbi Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI
    Ken Herrmann
    Department of Nuclear Medicine, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
    Mol Imaging Biol 13:1011-9. 2011
    ....
  2. ncbi Monitoring response to therapeutic interventions in patients with cancer
    Ken Herrmann
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    Semin Nucl Med 39:210-32. 2009
    ..In addition, the future direction of research and clinical applications is discussed...
  3. ncbi Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment
    Ken Herrmann
    Department of Nuclear Medicine, Technische Universitaet Muenchen, Munich, Germany
    J Nucl Med 52:690-6. 2011
    ....
  4. ncbi Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study
    Katja Ott
    Department of Surgery, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 14:2012-8. 2008
    ..The goal of the study was the definition of biologically different groups of patients prior to or early during induction therapy, with special emphasis on FDG non-avid tumors...
  5. ncbi Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine
    Florian Eckel
    Department of Internal Medicine II, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 50:1441-7. 2009
    ..We determined the ability of PET with the thymidine analog 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) to detect hepatocellular carcinoma (HCC)...
  6. ncbi [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer
    Murat Tuncel
    Department of Nuclear Medicine, Klinikum rechts der lsar, Technische Universitat Munchen, Munich, Germany
    Nucl Med Biol 35:689-95. 2008
    ..To evaluate [(11)C]Choline positron emission tomography (PET)/computed tomography (CT) for staging and restaging of patients with advanced prostate cancer and to compare the diagnostic performance of PET, CT and PET/CT...
  7. ncbi PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
    Florian Lordick
    Department of Surgery, Clinic rechts der Isar, Technical University of Munich, Munich, Germany
    Lancet Oncol 8:797-805. 2007
    ..We aimed to assess the feasibility of a PET-response-guided treatment algorithm and its potential effect on prognosis...
  8. ncbi A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma
    Ken Herrmann
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 52:1898-902. 2011
    ..Immunohistochemical analysis from core biopsy or lymph node may not represent the proliferation rate. We investigated the in vivo proliferation marker 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) to characterize MCL...
  9. ncbi (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial
    Christian Meyer Zum Büschenfelde
    3rd Department of Medicine Haematology and Medical Oncology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 52:1189-96. 2011
    ..Therefore, we initiated this prospective trial to improve the clinical outcome of metabolic nonresponders using a salvage neoadjuvant radiochemotherapy...
  10. ncbi Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction
    Hinrich A Wieder
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaningerstrasse 22, Munich, Germany
    Eur J Nucl Med Mol Imaging 34:1925-32. 2007
    ..To address this question we studied the time course of changes in tumor FDG-uptake in patients with locally advanced adenocarcinomas of the esophagogastric junction (AEG) treated with preoperative chemotherapy...
  11. ncbi [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model
    Bernd J Krause
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Ismaninger Str 22, 81675 Munchen, Munich, Germany
    Eur J Nucl Med Mol Imaging 37:1861-8. 2010
    ..11)C]Choline has been established as a PET tracer for imaging prostate cancer. The aim of this study was to determine whether [(11)C]choline can be used for monitoring the effects of therapy in a prostate cancer mouse xenograft model...
  12. ncbi The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT
    Robert Rosenberg
    Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaningerstr 22, 81675, Munich, Germany
    Int J Colorectal Dis 24:191-200. 2009
    ....
  13. ncbi Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment
    Nicolas Graf
    Department of Hematology and Oncology, Technische Universitat Munchen, Ismaninger Strasse 22, 81675, Munich, Germany
    Mol Imaging Biol 10:349-55. 2008
    ..In this preclinical study, we have investigated if FLT can also be utilized for imaging therapy-induced alterations of the nucleoside metabolism and if FLT is a surrogate marker for early response to cytotoxic treatment...
  14. ncbi Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine
    Andreas K Buck
    Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaninger Strasse 22, D 81675 Munich, Germany
    Methods 48:205-15. 2009
    ..Methods for in vivo assessment of the proliferative activity in preclinical and clinical studies are described with a focus on early monitoring response to therapy...
  15. ncbi Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism
    Stephan Metz
    Department of Radiology, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 51:1691-8. 2010
    ..We analyzed the spatial relationship of α(v)β(3) expression, glucose metabolism, and perfusion by PET and DCE MRI, focusing on tumor heterogeneity...
  16. ncbi FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy
    Zhoulei Li
    Nuclear Medicine, III Medical Department, Technische Universitat Munchen, Munich, Germany
    Cancer Res 72:5014-24. 2012
    ..In conclusion, we show that FLT-PET but not FDG-PET is able to predict response to treatment with specific inhibitors very early in the course of treatment and thus enables early prediction of treatment efficacy...
  17. ncbi Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis
    Ken Herrmann
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 48:1945-50. 2007
    ..In this pilot study, we evaluated 3'-deoxy-3'-(18)F-fluorothymidine (FLT) PET for the detection of gastric cancer and compared the diagnostic accuracy with that of (18)F-FDG PET...
  18. ncbi Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG
    Ambros J Beer
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 49:22-9. 2008
    ..We evaluated whether assessment of alpha(v)beta(3) expression and of glucose metabolism with PET using (18)F-galacto-RGD and (18)F-FDG provides complementary information in cancer patients...
  19. ncbi Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches
    Andreas K Buck
    Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
    J Nucl Med Technol 38:6-17. 2010
    ....
  20. ncbi Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response
    Rupert Langer
    Institute of Pathology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 14:8279-87. 2008
    ....
  21. ncbi [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner
    Nicolas Graf
    Department of Hematology Oncology, Technische Universitat Munchen, Munich, Germany
    Eur J Nucl Med Mol Imaging 40:34-43. 2013
    ..In this preclinical in vitro and in vivo study we compared [(18)F]FLT to the glucose analogue [(18)F]fluorodeoxyglucose ([(18)F]FDG) regarding dose-dependent visualization and prediction of early therapy response...
  22. ncbi Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy
    Tobias Maurer
    Department of Urology, Technische Universitat Munchen, Klinikum rechts der Isar, Munich, Germany
    Eur Urol 61:1031-8. 2012
    ..Current imaging techniques are of limited value for lymph node (LN) staging in bladder cancer (BCa) patients scheduled for radical cystectomy (RC)...
  23. ncbi Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches
    Andreas K Buck
    Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universitat Munchen, Munich, Germany
    J Nucl Med 51:401-12. 2010
    ....
  24. ncbi Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma
    Ken Herrmann
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 13:3552-8. 2007
    ....
  25. ncbi Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine
    Andreas K Buck
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 14:2970-7. 2008
    ....
  26. ncbi In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors
    Ken Herrmann
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 49:1437-44. 2008
    ..We have determined the ability of PET with the thymidine analog 3'-deoxy-3'-(18)F-fluorothymidine (FLT) to detect pancreatic cancer and to differentiate malignant from benign pancreatic lesions...
  27. ncbi The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration
    Michael Souvatzoglou
    Department of Nuclear Medicine, Technische Universitat Munchen, Munchen, Germany
    Clin Cancer Res 17:3751-9. 2011
    ..To evaluate the dependency of the sensitivity of [(11)C]choline positron emission tomography/computed tomography (PET/CT) for detecting and localizing primary prostate cancer (PCa) on tumor configuration in the histologic specimen...
  28. ncbi Pancreatic and hepatobiliary cancers
    Andreas K Buck
    Nuklearmedizinische Klinik und Poliklinik, Technische Universitat Munchen, Munchen, Germany
    Methods Mol Biol 727:243-64. 2011
    ..This chapter focuses on the use of PET-CT in hepatobiliary and pancreatic cancers...
  29. ncbi Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers
    Ken Herrmann
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    Nat Clin Pract Gastroenterol Hepatol 6:170-83. 2009
    ..Tissue-based and blood-based molecular biomarkers are still subject to validation. Prediction of response to treatment could ultimately lead to an overall improvement in prognosis...
  30. ncbi 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer
    Bernd Joachim Krause
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 50:89S-96S. 2009
    ..In the future, prospective randomized multicenter trials will have to be performed and research will address new imaging probes and innovative therapy regimens...
  31. ncbi PET and PET-CT in esophageal and gastric cancer
    Hinrich A Wieder
    Department of Radiology, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    Methods Mol Biol 727:59-76. 2011
    ..The role of FDG-PET in diagnosis, preoperative staging, monitoring of response to neoadjuvant therapy, and detection of disease recurrence is evaluated in this chapter...
  32. ncbi Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier
    Benjamin Balluff
    Department of Medicine II, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
    J Proteome Res 9:6317-22. 2010
    ....
  33. ncbi SPECT/CT
    Andreas K Buck
    Department of Nuclear Medicine, Technische Universitat Munchen, Munchen, Germany
    J Nucl Med 49:1305-19. 2008
    ..This review highlights recent technical developments in integrated SPECT/CT systems and summarizes the current literature on potential clinical uses and future directions for SPECT/CT in cardiac, neurologic, and oncologic applications...
  34. ncbi First demonstration of 3-D lymphatic mapping in breast cancer using freehand SPECT
    Thomas Wendler
    Technische Universitat Munchen, Boltzmannstr 3, 85748 Garching bei Muenchen, Germany
    Eur J Nucl Med Mol Imaging 37:1452-61. 2010
    ..In this pilot study, the feasibility of freehand SPECT for 3-D lymphatic mapping in breast cancer was evaluated...
  35. ncbi Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction
    Katja Ott
    Department of Surgery, Technische Universitaet Muenchen, Ismaningerstr 22, D 81675, Munich, Germany
    J Clin Oncol 24:4692-8. 2006
    ..The aim of this study was to prospectively validate these findings by using an a priori definition of metabolic response...
  36. ncbi Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2
    Ivonne Regel
    Department of Medicine II, Universitat Munchen, Munchen, Germany
    Gastroenterology 143:99-109.e10. 2012
    ..Histone deacetylase (HDAC) inhibitors modify chromatin and can block cancer cell proliferation and promote apoptosis...
  37. ncbi 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy
    Ken Herrmann
    Division of Surgical Oncology, University of California at Los Angeles, 10833 Le Conte Avenue, Rm 54 140 CHS, Los Angeles, CA 90095, USA
    Clin Cancer Res 18:2024-31. 2012
    ..We prospectively evaluated whether 2[18F]fluoro-2-deoxy-d-glucose ((18)F-FDG)-PET/computed tomographic (CT) imaging after the initial cycle of neoadjuvant therapy could predict overall survival in these patients...